I too am a chemist .. the chemistry sort..experience in toxicology,analytical etc. know of the hepatotoxicity of paracetamol when abused, the recent research link between ibuprofen and coeliac disease and maybe do have rose coloured glasses on thinking that the medical profession could be a little more open especially since W.H.O recently came out with " The ECDD therefore concluded that current information does not justify scheduling of cannabidiol and postponed a fuller review of cannabidiol preparations to May 2018, when the committee will undertake a comprehensive review of cannabis and cannabis related substances."
http://www.who.int/medicines/news/2017/WHO-recommends-most-stringent-level-int-control/en/
Cannabidiol (CBD)
There is increased interest from Member States in the use of cannabis for medical indications including for palliative care. Responding to that interest and increase in use, WHO has in recent years gathered more robust scientific evidence on therapeutic use and side effects of cannabis and cannabis components.
To that end, the ECDD did an initial review of a cannabis compound called cannabidiol (CBD). Recent evidence from animal and human studies shows that its use could have some therapeutic value for seizures due to epilepsy and related conditions. Current evidence also shows that cannabidiol is not likely to be abused or create dependence as for other cannabinoids (such as Tetra Hydro Cannabinol (THC), for instance).
- Forums
- ASX - By Stock
- Ann: MCL LEADS IN MEDICAL CANNABIS WITH CANADIAN DEAL
I too am a chemist .. the chemistry sort..experience in...
-
- There are more pages in this discussion • 406 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CGB (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online